Gene · 23521
NIH grants2,185
NIH grants whose papers are about the gene, through NIH's grant-paper links.
721 to 740 of 2,185
Download this page as JSON| Grant | Title | RPL13A papers | Newest fiscal year |
|---|---|---|---|
| ZIAAI000370 | Pathogenesis and Vaccine Studies Of Simian Immunodeficiency Virus Infection Of Monkeys | 1 | 2022 |
| R01CA105304 | Delineating the mechanisms of androgen receptor activation function-1 antagonists for development of novel prostate cancer therapeutics | 6 | 2021 |
| R01DK064989 | Cellular Mechanisms that Promote or Prevent Lipotoxicity | 5 | 2021 |
| ZIAHG200325 | Finding Genes for Human Prostate Cancer | 4 | 2021 |
| K08AI128745 | Regulation of Metabolic Programs for Host Tolerance to Inflammation | 3 | 2021 |
| R01CA218112 | Mechanisms of genome instability induced by APOBEC Cytidine Deaminases and its impacts during cancer development. | 3 | 2021 |
| R01ES027576 | DEVELOPMENTAL TOXICITY OF ORGANOPHOSPHATE-BASED FLAME RETARDANTS | 3 | 2021 |
| R25GM055036 | Expanding Participation by Minorities in Biomedical Sciences | 3 | 2021 |
| T32GM007175 | Pharmaceutical Sciences and Pharmacogenomics | 3 | 2021 |
| T32GM007753 | Medical Scientist Training Program | 3 | 2021 |
| T32GM007814 | Predoctoral Training Program in Human Genetics | 3 | 2021 |
| U54CA209891 | Research Center for Cancer Systems Biology: Cancer Cell Map Initiative | 3 | 2021 |
| DP2GM128203 | Combinatorial Biology of Gene Regulation for Cellular Engineering | 2 | 2021 |
| F32CA239333 | Systematic Targeting of Oncogene Interacting Proteins to Reveal New Therapeutic Strategies | 2 | 2021 |
| K08EY027474 | The Role of Wnt-regulated Collagen Dysfunction in Keratoconus | 2 | 2021 |
| P30DK079328 | UT Southwestern O'Brien Kidney Research Core Center | 2 | 2021 |
| R01HL132899 | Role of miR-574-Fam210a axis in cardiac hypertrophy and remodeling | 2 | 2021 |
| R01HL142665 | Molecular Determinants of Hemogenic Endothelium | 2 | 2021 |
| R35GM124693 | PARP-1 Signaling in DNA Damage and Cell Death | 2 | 2021 |
| R44CA203184 | CDK8/19 inhibitors for therapy of advanced prostate cancer | 2 | 2021 |
Source NIH's project filesgene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/23521/grants?page=37